GLUE (Monte Rosa Therapeutics) Forward Dividend Yield %: 0.00% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $21.97
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Forward Dividend Yield %?

Monte Rosa Therapeutics GLUE -4.52% 34 Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 148 Biotechnology companies, Monte Rosa Therapeutics ranks worse than 675675% on this metric.

As of today (2026-07-14), the Forward Annual Dividend Yield of Monte Rosa Therapeutics is 0.00%.

As of today (2026-07-14), the Trailing Annual Dividend Yield of Monte Rosa Therapeutics is 0.00%.

GLUE's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.275
* Ranked among companies with meaningful Forward Dividend Yield % only.

Monte Rosa Therapeutics's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Monte Rosa Therapeutics  (NAS:GLUE) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Monte Rosa Therapeutics Forward Dividend Yield % Related Terms

GLUE vs SNDX, IOVA, TYRA: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Monte Rosa Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's Forward Dividend Yield % falls into.


GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Monte Rosa Therapeutics (GLUE) has a Forward Dividend Yield % of 0.00% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Monte Rosa Therapeutics and its competitors. According to the industry distribution chart, Monte Rosa Therapeutics ranks #999999 out of 148 companies in the Biotechnology industry.
Is Monte Rosa Therapeutics' Forward Dividend Yield % too high?
Monte Rosa Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Monte Rosa Therapeutics ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Forward Dividend Yield % compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #999999 out of 148 companies for Forward Dividend Yield %. This places Monte Rosa Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.28, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Monte Rosa Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monte Rosa Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.97
Price